Cell News and Research

RSS

Hamilton Thorne launches new Stiletto laser for regenerative medicine and stem cell research markets

Hamilton Thorne Ltd., a leading provider of advanced laser systems for the regenerative medicine and stem cell research markets, today announced the launch of its new Stiletto™ laser system. The Stiletto™ laser system has broad applications for research with a variety of cells, allowing the Company to enter new and exciting research markets, including developmental and advanced cell biology.

9 Dec 2010

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Nitric oxide attacks key groups of proteins critical to cell survival

Nitric oxide is a toxic pollutant, but the human body also creates it and uses it to attack invading microbes and parasites. A new study by researchers at UC Davis, the Massachusetts Institute of Technology and the Japan Synchrotron Radiation Research Institute (JASRI) shows how nitric oxide, attacks an important group of proteins critical to cell survival.

9 Dec 2010

Researchers discover central switch that regulates movement of cancer cells

Researchers at the University of Georgia have discovered a central switch that controls whether cells move or remain stationary. The misregulation of this switch may play a role in the increased movement of tumor cells and in the aggressiveness of tumors themselves.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Walter and Eliza Hall Institute researcher awarded 2011 Gani Medal for Human Genetics

Major advances in our understanding of human evolution have seen Walter and Eliza Hall Institute researcher Dr Alicia Oshlack awarded the 2011 Gani Medal for Human Genetics by the Australian Academy of Science.

9 Dec 2010

Laparoscopic approach still best for most patients, not for all: Study

If skin is the body's fortress against germ invaders, shouldn't minimally invasive surgeries - operations guided by camera probes, conducted entirely within the abdomen - carry less risk for serious infection than procedures that slice the same cavity wide open?

9 Dec 2010

Study: States fund majority of human embryonic stem cell research conducted in the US

States, not the federal government, now fund the majority of human embryonic stem cell research conducted in the United States, according to a recent study in the journal Nature Biotechnology.

9 Dec 2010

Creation of two-father offspring in mice, a step toward preserving endangered species

Using stem cell technology, reproductive scientists in Texas, led by Dr. Richard R. Berhringer at the M.D. Anderson Cancer Center, have produced male and female mice from two fathers.

9 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

European researchers develop new form of therapy for Alpha-mannosidosis

Alpha-mannosidosis is a rare childhood disease which causes symptoms such as mental retardation or hearing loss and is linked to a lower life expectancy. A European research team headed by Professor Paul Saftig from Christian-Albrechts-Universit-t zu Kiel has developed a form of therapy as part of the Alpha-Man project, which will receive around six million euros from the European Union for its next stage of trials.

9 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.

9 Dec 2010

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.

9 Dec 2010

Organovo releases data on bioprinted blood vessels

Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.

9 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

Cell News and Research

Hamilton Thorne launches new Stiletto laser for regenerative medicine and stem cell research markets

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Nitric oxide attacks key groups of proteins critical to cell survival

Researchers discover central switch that regulates movement of cancer cells

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Walter and Eliza Hall Institute researcher awarded 2011 Gani Medal for Human Genetics

Laparoscopic approach still best for most patients, not for all: Study

Study: States fund majority of human embryonic stem cell research conducted in the US

Creation of two-father offspring in mice, a step toward preserving endangered species

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

European researchers develop new form of therapy for Alpha-mannosidosis

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Organovo releases data on bioprinted blood vessels

Medulloblastoma subtypes are separate diseases with different origins

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics